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Abstract: Inflammatory bowel disease (IBD) is a chronic disease mediated by the immune system
and is characterized by inflammation of the gastrointestinal tract. One of the possible treatments for
this pathology is a change in the type of diet, of which enteral nutrition (EN) is one. This study is to
understand how the use of EN can affect the adult population diagnosed with IBD. We conducted
a systematic review, meta-analysis, and a meta-regression. On the different databases (MEDLINE,
Scopus, Cochrane, LILACS, CINAHL, WOS), we found 363 registers with an accuracy of 12%
(44 registers). After a full-text review, only 30 research studies were selected for qualitative synthesis
and 11 for meta-analysis and meta-regression. The variables used were Crohn’s disease activity index
(CDAI), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). EN has been shown to
have efficacy for the treatment of Crohn’s disease and is compatible with other medicines. As for
the CDAI or rates of remission, there were no differences between enteral and parenteral nutrition.
Polymeric formulas have shown better results with respect to the CRP. The long-term treatment could
dilute the good CDAI results that are obtained at the start of the EN treatment.
Keywords: inflammatory bowel diseases; enteral nutrition; systematic review; meta-analysis;
Crohn’s disease
1. Introduction
Inflammatory bowel disease (IBD) is a chronic disease mediated by the immune system and
characterized by the inflammation of the gastrointestinal tract. IBD includes Crohn’s disease (CD) as
well as ulcerative colitis (UC) [1]. UC affects the large intestine and is generally observed as a superficial
ulcer due to an inflammatory reaction localized to the mucosa and the submucosa. However, CD occurs
all along the intestinal tract (from mouth to anus) and involves the entire intestinal layer [2].
The prevalence and incidence of IBD has increased worldwide and is increasingly diagnosed in
young individuals [3]. As it is a chronic, incurable, and low-mortality disease, it is expected that the
decrease of the global burden of the disease in the next decade will require a two-pronged solution that
implies research on prevention interventions as well as innovations in the care of these patients [3,4].
The etiology of IBD is still greatly unknown, and recent evidence indicates that the genetic
susceptibility of the individual, the environment, the intestinal microbial flora, and the immune
responses are all factors that are involved and functionally integrated in the pathogenesis of IBD [5].
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IBD can provoke various symptoms that include abdominal pain, low fever, fatigue, weight loss,
diarrhea, bloody feces, etc. [6].
Within the identification of the environmental risk factors, diet is one of the most important as
it regulates intestinal inflammation by modifying the intestinal microbiota, which has an effect on
the gastrointestinal permeability [7,8]. Therefore, it can induce the expression of disease genes and
determine the cell’s phenotype and function in IBD [7,8]. One of the possible treatments for this
pathology is a change in the type of diet [9].
One of the potential changes in diet is the use of enteral nutrition (EN), which is based
on the administration of enteral foods/formulas through different means. These foods are
nutritionally-complete liquid mixtures of pre-digested foods that have carbohydrates such as simple
sugars, fats such as different types of oils, and nitrogen as protein, along with vitamins and minerals [10].
Within the elemental formulas, different classes can be distinguished as a function of the nitrogen source:
elemental formulas are based on amino acids, semi-elemental formulas are based on oligo-peptides,
and polymeric formulas are based on whole proteins [11].
Diverse authors have highlighted that EN, especially in the form of exclusive enteral nutrition
(EEN), is a type of therapy established to induce the remission of CD in the infant population, although
its role as a first line therapy for CD in adults has not been defined yet and its mechanism of action for
palliating the symptoms of IBD is not completely understood [9,12]. Authors such as Guagnozzi et al.
suggest that the interaction between the composition of specific dietary formulas or nutrients and IBD
should be investigated to add new knowledge to the etiopathogenesis of the disease in nutritional
intervention [13].
Therefore, the main objective of this study was to understand how the use of EN can affect the
adult population diagnosed with IBD.
2. Materials and Methods
To achieve this objective, a systematic review was conducted in agreement with the procedures
and verification list described by PRISMA [14]. Afterward, a meta-analysis on the more common
results and a meta-regression with the co-variables, type of enteral nutrition, and period of treatment,
were conducted.
2.1. Systematic Review
A search of scientific works was conducted in the MEDLINE database through the system of
open retrieval system on the Internet such as PubMed, Cochrane, Scopus, Web of Science, CINAHL,
and LILACS. Studies conducted over time up to 5 January 2019 were compiled.
2.1.1. Inclusion and Exclusion Criteria
The studies selected had to comply with the following inclusion criteria: refer to an adult
population (older than 18) diagnosed with some type of IBD; study the effect of enteral nutrition within
IBD; were clinical trials; and in the English, Spanish, Portuguese, French, or German languages.
The following articles were excluded: those that referred to the infant population; to animals, to
the use of EN in a healthy adult population; those that sought the effect of oral exclusion diets on IBD;
observational studies; and those based on secondary sources.
2.1.2. Search Equation
To include content linked to the intervention EN, a specific descriptor was used (MeSH) such as
“Enteral Nutrition”, and the term “Enteral Nutrition” in the title or abstract.
For the content linked to the population, we utilized the descriptor that referred to the disease
“Inflammatory bowel diseases”, and its equivalent term in the title or abstract.
Additionally, the filters “Humans”, “Adult”, and “Clinical Trial” were utilized to achieve
our objective.
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Therefore, the main search equation designed for this study was:
((“Inflammatory Bowel Diseases”[Mesh] OR “Inflammatory Bowel Diseases”[Title/Abstract])
AND (“Enteral Nutrition”[Mesh] OR “Enteral Nutrition”[Title/Abstract])) AND (Clinical Trial[ptyp]
AND Humans[Mesh] AND adult[MeSH])
The search equation was adapted to each and all of the databases described previously. The process
was conducted between the months of May and June, 2019.
2.1.3. Selection Process
After eliminating the duplicate records, the process of selection was conducted in two phases.
The first consisted of reviewing the titles and abstracts of all the article records that resulted from
the adapted search equations and were shown by the databases by using the inclusion and exclusion
criteria and the objective of the study as the screening measure. The screening and selection of the
records/articles were conducted independently by the two researchers, both experts in the fields of
nutrition. These researchers agreed on the discrepancies found in order to define the final suitability of
the records/articles found in the databases. The precision of the search was calculated, based on the
ratio of the full-text articles selected for the review, divided by the number of records found by the
search equation, and multiplied by one hundred.
The second phase was conducted by applying the inclusion/exclusion criteria to the complete texts
of all of the scientific studies selected in the first phase, thus ensuring the relevance of each one. In order
to obtain studies that were not accessible via the Internet, we used three methods: Researchgate, the
correspondence author, and interlibrary loan. Only three were recovered through interlibrary loan.
2.1.4. Evaluation of the Quality of the Studies
The evaluation of the methodological quality of the included studies was performed by two
independent researchers by using the Cochrane risk of bias tool (RoB 2) for clinical trials [15]. This tool is
structured into five domains through which bias might be introduced into the result: the randomization
process, deviations from intended interventions, missing outcome data, measurement of the outcome,
and selection of the reported results. For each study, the response options for an overall risk-of-bias
judgement were “low risk of bias”, “some concerns”, and “high risk of bias”.
2.2. Meta-Analysis and Meta-Regression
To calculate the effect size of the enteral nutrition on the variables: the Crohn’s disease activity
index (CDAI), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), a meta-analysis,
were performed. For this, the model of fixed effects and the model of random effects were utilized.
The results were presented as a forest-plot, along with the percent heterogeneity and its confidence
interval at 95%, the T value, and the heterogeneity test.
To explore the influence of each study over the effect size, we used a leave-one-out method;
pooled estimates were calculated by omitting one study at a time. In addition, we plotted a scatter plot
introduced by Baujat et al. [16] On the x-axis, the contribution of each study to the overall heterogeneity
statistic was plotted. On the y-axis, the standardized difference of the overall treatment effect with
and without each study was plotted; this quantity describes the influence of each study on the overall
treatment effect. Therefore, studies that fell in the top right quadrant of the Baujat plot had the
most influence.
Publication bias occurs when only favorable results are published, and this could have
consequences on the results of the meta-analyses if these were included. To analyze the publication
bias, a non-parametric analysis was conducted as proposed by Duval and Tweedie [17], based on
the funnel-plot, estimating and adjusting for the number and outcomes of missing studies in the
meta-analysis. Another less-conservative proposal to estimate the number and outcomes of missing
studies was proposed by Copas et al. [18].
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The meta-regression was utilized to understand if the type of enteral nutrition (polymeric or
elemental), age (years), or the duration of the intervention (days) modified the effect size of the resulting
variables CDAI, CRP, and ESR as a function of the type of nutrition. All the calculations were conducted
within an R programming environment by utilizing the packages meta version 4.9-6 [19] and metasens
version 0.4-0 [20].
3. Results
3.1. Systematic Review
As a result of the specific search equations used on the different databases, a total of 438 records of
scientific articles were found. A total of 75 records were duplicated, leaving a total of 363 records without
duplication. In the first phase of the study, exactly 319 study records were discarded, leaving 44 full-text
studies to review, so the accuracy was 12%. The reasons for not including them were that 131 records
showed that the study utilized a design that was not adequate, 100 did not use an adult population,
50 did not study the effect of EN, three were written in another language other than the ones cited
above, (two in Japanese and one in Chinese), 12 did not refer to humans, six did not refer to the IBD,
and 17 were conducted without showing results (Figure 1).Nutrients 2019, 11, x FOR PEER REVIEW 5 of 24 
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Figure 1. Identification and selection of the studies/records in the databases.
In the second phase, seven studies were not utilized as they could not be obtained in electronic
format, not even after using the methods explained in the methodology. In addition, seven trials
were removed, one for being written in Turkish, another due to defects in its design, another for not
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studying the effects of EN, and four because the population studied was not diagnosed with IBD.
Therefore, only 30 research studies [10,21–49] were selected, as shown in Figure 1.
As for the designs of the studies included, 16 controlled and randomized clinical studies (53.3%),
nine non-randomized, controlled clinical trials (30%), and five non-randomized, non-controlled clinical
trials (16.7%) were found. In addition, 28 of the studies found showed results that specifically referred
to CD, and two studies had results on UC and CD, under the category of IBD. Additionally, 23 studies
mentioned results of the disease in its active form, four studies in the shape of remission, and the rest
did not indicate any. Figure 2 shows this information in a chronological manner.
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In addition, a total of six types of objectives were found: 10 studies sought to compare two different
types of EN, among which five of the works compared an elemental formula with a polymeric one,
two compared an elemental formula with another elemental one that contained a greater concentration
of fats, one work compared two types of polymeric formulas, one work compared two types of
elemental formulas, and one work co pared an elemental for ula with a semi-elemental one.
Moreover, seven studies compared a type of EN with an oral diet, five studies sought to experiment
with a type of EN, three studies compared a type of EN ith a type of PN, three studies sought to
compare a type of EN with another type of medication plus an oral diet, and finally, two studies sought
to compare a partial EN plus a diet with an oral diet.
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As for the manner of administration of the EN, 15 research studies employed a nasogastric tube,
three studies utilized a nasoduodenal catheter, two studies used a nasointestinal catheter, seven studies
administered the formula orally, and three did not specify the manner of administration.
The total population analyzed in the research studies found included a total of 1070 individuals
with IBD, with 1016 diagnosed with CD and 25 with UC.
The main tools utilized by the researchers to obtain results were scores, biomarkers, and tests
to measure the activity of the disease: “Harvey–Bradshaw Index” (HBI), the CDAI, the Van Hees
activity index (VHAI), the qualification in the classification of the International Organization of
Inflammatory Bowel Disease (IOIBD), the Subjective Global Assessment (SGA), the Truelove and
Witts index, the simple clinical index, the Crohn’s disease activity score (CDAS); biomarkers such as
CRP, ESR, the white blood cell count (WBC), levels of albumin, pre-albumin, transferrin, hemoglobin,
platelet count, total bilirubin, alkaline phosphatase, etc.; and medical tests such as ileocolonoscopy.
Specific quality of life questionnaires such as the “Inflammatory Bowel Disease Questionnaire” (IBDQ)
were also used as were complementary tests such as urine and feces samples and tests to measure the
body’s composition such as anthropometries and bioimpedence.
Table 1 shows the main results schematically, as found in the selected articles. Figures 3 and 4
show the scores obtained by the studies for their methodological quality, according to the Cochrane
risk of bias tool.
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Figure 3. Risk of bias summary across the clinical trials. Low risk of bias: green “+”; Some concerns of
bias: yellow “?”, “!”; High risk of bias: red “−”.
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Table 1. Main results of the systematic review.
Author Study n/age Disease P/d CC Treatment Variables Main Results
Walton et al. 2016 [10] UNRCT 17/- ACTCD 14 GB
Enteral feeding E028 extra
(Elementary diet)
CRP, HBI and automated
spectral identification in feces
The HBI decreased from 6.88 ± 2.93 to 4 ± 5.50, (p < 0.05), the CRP from 36.0
± 41.3 mg/L to 8.11 ± 3.59 (p < 0.05), the concentration of 1-propanol and
1-butanol decreased too. No modifications in phenol and indole. The SCFA
esters disappeared.
Pinar Sökülmez et al.
2014 [21] RCCT
38/37
M 28
F 10
ACT
IBD
EG/CG: 15/23
CD
EG/CG: 6/7
UC
EG/CG: 9/16
21 TR
EG/CG
Diet and EN
Novasource®/Unrestricted
Diet
SGA, BMI, nausea, vomiting,
bowel movements, change in
malnutrition state, general
status, and disease severity.
Although at the beginning of the study the proportion of patients with a
severe UC in the EG was higher than in the CG (8/9, and 7/16 respectively),
there were no significant differences at the end of the study (p > 0.05). In
both groups the improvements in disease activity of patients with UC were
significant, but non-significant positive changes were observed in the
clinical findings during the hospitalization period. Significant
improvements of the SGA in both groups.
Dong Hu et al.
2014 [22] UNRCT
59/32
M 42
F 17
ACT
CD 84 CN
Elemental formula Peptide
(Nutricia) through nasogastric
or nasointestinal tube, plus
water and weak tea.
Symptoms, CDAI, peripheral
blood samples. Laboratory
tests, including nutritional
parameters and inflammatory
parameters and CT.
50 patients achieved a partial remission, 30 a complete remission. 48
symptomatic remission, 35 radiological remission and 42 clinical remission.
The CDAI decreased from 188.2 to 132.4 in 21 days (p < 0.05), and to 92.9
after 81 days (p < 0.05). Significant decrease in the thickness of the intestinal
wall and an increase in the area of the luminal cross section. CRP and ESR
decreased significantly (p < 0.05), the BMI, albumin, prealbumin and
transferrin, HB, platelets, red blood cells, globulin and total protein
increased significantly (p < 0.05).
Zhen Guo et al.
2013 [23] UNRCT
13/26
M = 9
F = 4
ACT
CD 28 CN
Exclusive EN through polymer
formula Administration:
Nasogastric tube at night and
orally by day. They allowed
water consumption.
IBDQ, CDAI, BMI, CRP, ESR,
WBC count, HB and serum
albumin level in peripheral
venous blood.
11 patients achieved clinical remission and 2 did not. CDAI and CRP
decreased from 232.2 and 34.6 to 84.7 and 4.0 (p ≤ 0.001). Significantly
decreased the number of liquid or soft stools, abdominal pain, general
well-being and percentage deviation of the standard weight (p < 0.05), no
differences were found in the presence of complications, taking
atropine/diphenoxylate or opiates, presence of a mass abdominal and
hematocrit. There were significant improvements in the IBDQ, from 128.3 to
182.9 (p < 0.001). Significant improvement in all categories: intestinal
symptoms (from 41.5 to 62.0, p < 0.001), systemic symptoms (16.5 to 27.5,
p < 0.001), social function (20.5 to 26.5, p = 0.03) and emotional state (49.8 to
66.9, p < 0.001). Correlation between IBDQ and CDAI after treatment
(r = −0.57; p = 0.042).
Feng Y et al. 2013 [24] NRCCT
24/33
M 17
F 7
ACT
CD
ENG/NoEN/CG
8/8/8
28 CN
ENG: Enteral formula
“Peptisorb” by nasogastric
tube, plus water. NoENG: EC
patients without EN. CG:
Patients with colon carcinoma.
Adipocyte size, adipokine
production and level of CRP
were evaluated. Leptin,
resistin, TNF, and IL-6 and
IL-10 levels were determined.
BMI, CDAI, etc. were
calculated.
ENG patients had a higher BMI level and lower levels of CRP and CDAI
(p < 0.001) and achieved clinical remission (CDAI < 150). In addition,
protein levels of proinflammatory adipokines (TNF-alpha and leptin) were
lower, leptin was negatively regulated, and adipokine expression (mRNA
level) was positively regulated. In the NoEN group the level of adiponectin
protein was higher
Dawn M. Wiese et al.
2011 [25] NRCCT
20/46
M 4
F 16
ACT
CD
EPA>2%/EPA<2%
10/10
120 US
Two 8-oz each day of NE
EPA>2% or EPA<2%
respectively.
CDAI, IBDQ, nutritional status,
micronutrient levels, CRP and
body composition among
others were measured.
EPA > 2% group increased the BMI, fat mass, fat-free mass, IBDQ (+41.4
[23.1, 47.0]; p = 0.002) and the CDAI decreased (−47.8 [−65, −37.8]; p = 0.05).
There were no differences between groups for the rest of the variables
studied.
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Table 1. Cont.
Author Study n/age Disease P/d CC Treatment Variables Main Results
Takayuki
Yamamoto et al.
2010 [26]
NRCCT
56/32
M 36
F 20
REM
CD
EG/CG
32/24
392 JP
EG. Elemental formula
“Elental” by nasogastric tube at
night and low-fat foods during
the day.
CG. Unrestricted Diet
WBC, HB, hematocrit, platelet
count, ESR, CRP and albumin.
CDAI. Symptoms, adverse
effects, stool parameters.
The CDAI did not decrease significantly. No differences were observed
between the groups. (p = 0.51). The cumulative proportion of patients in
clinical remission was not significantly different between the groups.
Takayuki
Yamamoto et al.
2006 [27]
NRCCT
40/32
M 26
F 14
ACT
CD
EG/CG
20/20
+365 JP
EG: Elemental formula
“Elental” by nasogastric tube at
night and low-fat foods during
the day.
CG. Unrestricted Diet
WBC, HB, platelet count, ESR,
CRP and albumin. CDAI and
parameters by ileocolonoscopy.
During the year of follow-up, 1 patient of the EG and 7 in the CG developed
clinical recurrence (p = 0.048). At 6 months, 5 patients of the EG and 8 of the
CG developed endoscopic recurrence (odds ratio, 2.0; p = 0.50). At 12
months, 6 patients from the EG and 14 from the CG showed endoscopic
recurrence (odds ratio, 5.4; p = 0.027)
S. Takagi et al. 2006 [28] RCCT
51/30
M 37
F 14
REM
CD
EG/CG
26/25
730 JP
EG: Half of calories, elementary
diet through a enteral or oral
intake and the remaining half
by regular meals.
CG: Unrestricted Diet
CDAI. Parameters of: feces,
symptoms and laboratory tests.
After an average follow-up of 11.9 months, the relapse rate in the EG was
significantly lower than in the CG [34.6% vs. 64.0%; Multivariate risk ratio
0.40 (95% CI: 0.16–0.98)]. No significant changes on the rest of the variables
Tadao Bamba et al.
2003 [29] RCCT
28/28
M 17
F 11
ACT
CD
Low/
Medium/
High Fat EN
10/10/8
28 JP
LOWG: 6 packages of
elemental diet “Elental” and 6
packages of dextrin
MEDG: 6 packages of
elemental diet “Elemental”, 3
packages of dextrin and 3
packages of dextrin C-1
(dextrin + soybean oil).
HIGHG: 6 packages of
elemental diet "Elemental" and
6 packages of dextrin C-1.
Administration: Nasogastric
tube.
IOIBD, inflammatory markers
(CRP, ESR) and body weight
were recorded at each
follow-up.
No differences in body weight gains. The LOWG’s IOIBD was significantly
higher than in the MEDG and HIGHG groups (p = 0.048) and the CRP lower
after the first week.
In the MEDG and HIGHG groups the CRP fluctuated during the study. In
the LOWG group the ESR decreased, but for the other groups they
remained high or increased during the study.
Clinical remission was achieved in 8, 4 and 2 patients in the LOWG, MEDG
and HIGHG groups respectively. This remission rate is significant if
grouped in LOWG vs. MEDG & HIGHG (p = 0.046).
M A Gassull et al.
2002 [30] RCCT
62/29
M 24
F 29
ACT
CD
PEN1/PEN2/ESTG
20/23/19
28
ES
GB
DE
PEN 1: Polymeric EN, rich in
n9 monounsaturated fatty
acids (MUFA) (oleic acid).
PEN 2: Polymeric EN rich in
n6 polyunsaturated fatty acids
(PUFA) (linoleic acid)
ESTG (Steroid group):
Prednisone.
ESR, CRP, serum fibrinogen,
VHAI, CDAI, NRI, serum
albumin and grip strength
The intention-to-treat analysis showed that the remission rates were 20%,
52% and 79% for PEN1, PEN2 and ESTG (p = 0.001). Withdrawal from
treatment, remission rates were 27%, 63% and 79%, respectively (p = 0.008).
No differences in remission time and changes in activity rates, inflammatory
biological parameters, NRIs and nutritional variables.
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Toshihiro Sakurai et al.
2002 [31] RCCT
36/26
M 30
F 6
ACT
CD = 36
EDG/TLG
18/18
42 JP
EDG: “Elental” Formula
(Ajinomoto Pharma) low in fat.
TLG: Twinline Formula
(Otsuka Pharma) large amount
of medium chain triglycerides
Administration: Tube in the
duodenum.
CDAI, VHAI, CRP, ESR, levels
of: serum albumin, plasma
prealbumin, plasma transferrin
and retinol binding protein in
plasma and triene/tetraeno
ratio.
After 2 weeks, serum levels of linoleic acid, an omega 6 fatty acid, decreased
significantly in the EDG group. Without significant differences was
observed: a short-term remission in 67% in the EDG and 72% in the TLG, a
reduction in the CDAI and the VHAI, a normalization of the CRP and an
improvement in the ESR and levels serum; albumin, plasma prealbumin,
plasma transferrin and plasma retinol binding protein, the linolenic acid
levels decreased in both groups.
S. Verma et al. 2000 [32] NRCCT
39/40
M 12
F 27
REM
CD
EG/CG
21/28
365 GB
EG: Oral nutritional
supplementation with
elemental diet “EO28 Extra”,
plus normal diet.
CG: Unrestricted Diet.
CDAI, inflammatory markers
such as CRP, ESR, albumin, HB
and platelet count.
The intention-to-treat analysis showed that the remission rates were 48%
and 22% for EG AND CG (p = 0.0003). Withdrawal from treatment,
remission rates were 60%, and 22%, respectively (p < 0.00001). Without
showing significant differences were observed: a stability of the levels of
CDAI and albumin and an increase in BMI. A significant decrease in ESR
was observed
Verma S et al. 2000 [33] RCCT
21/35
M 8
F 13
ACT
CD
GA/GP
11/10
28 UK
GA: Free amino acids diet.
GP: Polymeric diet.
Administration: nasogastric
tube. Water was allowed.
CDAI, inflammatory markers
(CRP, etc.), BMI and body
weight.
Clinical remission was achieved in 8 (80%) and 6 (55%) patients in the GA
and GP groups, respectively (without significant differences, p = 0.1). In
both groups CDAI (GA, 359 ± 67 to 112 ± 19, p ≤ 0.0002; GP, 303 ± 27 to 97 ±
11, p ≤ 0.0005) and CRP (GA, 16 ± 5 to 4 ± 1.6, p < 0.1; GP, 62 ± 20 to 9 ± 6,
p < 0.04) decreased. Remission was achieved earlier in GA (7 ± 2 days) than
in GP (14 ± 2 days) (without significant differences). Overall, enteral
feeding was successful in 14 patients (63%).
Bruno Schneeweiss et al.
1999 [34] NRCCT
26/28
M 9
F 17
ACT
CD
EG/CG
7/19
15 AT EG: 7 patients received enteralnutrition by nasogastric tube
Energy expenditure, UNP,
changes in the body’s urea
nitrogen set and body
composition.
The REE did not change. From day 7 the UNP, RQ and RQ without proteins
increased significantly. These changes (except carbohydrate oxidation rates)
were reversed when the EN was interrupted.
Dawna Royall et al.
1995 [35] NRCCT
60/30
M 32
F 28
ACT
CD
EG/CG
30/30
21 CA
EG: one of two elementary
diets, Peptamen or
Vivonex-TEN, administered by
nasoduodenal tube.
Total body protein, fat, water
and body potassium.
Compared to the CG, the EG lost 11.3 kg (p < 0.0005), (5.1 kg fat (p < 0.0005),
2.2 kg protein (p < 0.025), 3.7 kg water, 24.9 g body potassium (p < 0.01)).
After EN, body weight (1.9 ± 0.3 kg; p < 0.0005), body protein (0.3 ± 0.1 kg;
p < 0.025), fat (0.3 ± 0.1 kg; p < 0.025) and water (1.1 ± more; 0.4 kg; p < 0.025)
was significantly increased. Body potassium increased but not significantly.
Mansfield JC et al.
1995 [36] RCCT
44/-
M 16
F 28
ACT
CD
GA/GP
22/22
28 GB
GA: Enteral formula based on
amino acids “Elemental 028”.
GP: Enteral formula based on
oligopeptide-based diet
“Pepti-2000 LF liquid”. Water
was allowed.
CDAI, laboratory activity
measures (HB, platelet count,
ESR, serum albumin
concentration, AAGP and CRP)
and body weight.
16 patients (36.4%) achieved clinical remission and decreased CRP (p = 0.05).
Both groups had identical rates of remission, failure, early withdrawal and
nasogastric feeding intolerance. There was an increase in serum albumin in
patients who started the study at a low level.
Teahon K et al.
1995 [37] UNRCT
19/37
M 10
F 9
ACT
CD 35 GB
Elemental diet “Vivonex” was
using in one group (n = 8) and
“Elemental 028” in the other
(n = 11), by oral route.
CDAS, biochemical parameters
(HB, platelet count, leukocytes,
ESR, iron, magnesium, copper,
zinc . . . ), fecal parameters,
BMI and body composition.
Changes were similar in both groups. Clinical disease activity and fecal
excretion of leukocytes were significantly reduced after 2 weeks of
treatment. Transferrin, prealbumin, albumin and serum iron were
significantly increased at 4 weeks. Serum copper decreased during the
study period. Changes in nutrition measures did not correlate significantly
with changes in disease activity.
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M.F.J. Stolk et al.
1994 [38] UNRCT
6/27
M 3
F 3
CD 42 NL
By using a pump, the formula
“Peptison” (Nutricia) was
supplied.
Volume, motility, emptying
and filling variables of the
gallbladder were calculated,
and concentration of CCK in
the plasma
At the start of treatment, the fasting gallbladder volume decreased from
19.3 +/− 4.5 to 4.9 +/− 3.6 mL. The CCK increased from 1.5 +/− 0.3 to 3.9 +/−
1.1 pmol/L. After 8 days, the gallbladder contracted almost completely, the
CCK increased to 7.5 +/− 2.7, and at 36 days, CCK increased to 8.3 +/− 2.6
pmol/L. After 22 days 22 the volume of the gallbladder increased, and after
46 the CCK decreased. This change was significantly greater than the CCK
change on day 1 (p < 0.05)
D Royall et al. 1994 [39] RCCT
40/31
M 23
F 17
ACT
CD
AG/PG
19/21
21 CA
AG: Enteral formula based on
amino acids “Vivonex-TEN”.
PG: Enteral formula based on
peptides “Peptamen”.
Administered by nasogastric
tube. Water was allowed.
CDAI, CRP, AAGP,
phospholipids, albumin and
transferrin. Body weight and
total body nitrogen was
evaluated.
After 21 days, remission rates were equivalent between the two groups:
84% for the AG and 75% for the PG (p = 0.38). At 12 months, it remained at
31% and 40% respectively (p = 0.39).
Also, the reductions of CDAI, AAGP and CRP were significant. Linoleic
acid decreased and total body nitrogen increased significantly in AG but not
in PG (p < 0.025). The concentration of phospholipids in plasma increased
significantly in the PG
F González-Huix et al.
1993 [40] RCCT
32/31
M 17
F15
ACT
CD
PENG/ESTG
15/17
28 ES
PENG: The polymeric EN
administered by nasogastric
tube.
ESTG: Prednisone
administration. And diet
lactose-free while they were in
the hospital.
VHAI, CRP. Evaluation of body
weight, % IBW, MAMC, TSF,
serum albumin concentration.
Complete hematological and
biochemical analysis.
There were no significant differences in the mean time (p = 0.47) and the
number of patients who obtained clinical remission (p = 0.43). The VHAI
decreased in both groups; PENG from 172.5 to 113.8, (p = 0.0001), ESTG
from 184.3 to 118.1, (p = 0.0003). In both groups the CRP decreased and the
serum albumin concentration increased significantly. After one year, 10
patients (66.6%) in the ESTG and 5 (41.6%) in the PENG relapsed. No
differences in the cumulative probability of relapse.
Hiroyuki
Hirakawa et al.
1993 [41]
NRCCT
61/25
M 39
F 22
REM
CD
ENG/ENG+D/DG/CG
25/22/8/6
60 JP
ENG: Elemental EN (“Elental”)
through nasoenteral tube.
ENG+D: 12 ENG +
1
2 Low-fat
diet and prednisolone
DG: Low-fat diet and
prednisolone CG: Unrestricted
Diet
IOIBD, ESR and CRP
The cumulative rates of continuous remission after 1, 2 and 4 years were in
the ENG 94%, 63% and 63%; in the ENG + D 75%, 66% and 66% in the DG
63%; 42% and 0%, and in the CG 50%, 33%. and 0%. The ENG had a higher
rate than DG (p < 0.05) and CG (p < 0.01). The ENG + D had a higher rate
than the CG (p < 0.05). Patients who received more than 30 kcal of EN
showed a higher continuous remission rate (p < 0.001).
D Rigaud et al.
1991 [42] RCCT
30/35
M 18
F 12
ACT
CD
EENG/PENG
15/15
28 FR
EENG: Elementary enteral
formula “Vivonex HN”
PENG: “Realmentyl”
polymeric formula
CDAI, fecal production,
colonoscopies. Body weight;
TSF, MAMC, daily urinary,
creatinine-height ratio; blood
levels of HB, albumin and
transferrin. ESR, α2 globulin
level and WBC counts.
The clinical remission was in the EENG of 66% and in the PENG of 73%.
The CDAI and ESR levels were significantly reduced in both groups.
There were no differences between groups for inflammatory markers,
colonoscopic lesions, fecal production, body weight and creatinine index.
Herbert Lochs et al.
1991 [43] RCCT
107/29
M 37
F 70
ACT
CD
OENG/CSG
55/52
42 DE
OENG: Enteral nutrition by
oligopetidic formula
“Peptisorb” through
nasogastric or nasoduodenal
tube. More tea or water.
CSG: Combination of
corticosteroids and
sulfasalazine.
CDAI and laboratory tests.
After 6 weeks, 29 patients achieved remission in the OENG and 41 patients
in the CSG (p < 0.01). The remission time was significantly different
(p < 0.01). A CDAI below 150 was achieved in the OENG in 24 patients and
in the CSG in 35. The CDAI and severe malnutrition parameters showed no
significant differences in patients in remission.
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A.H. Raouf et al.
1991 [44] RCCT 24/-
ACT
CD
EENG/PENG
13/11
21 GB
EENG: Enteral amino
acid-based food “EO28”
PENG: Whole protein-based
whole food “Triosrbon”.
Administration: Oral, flavored
with Nesquick.
ESR, erythrocytes, VHAI, Bristol
simple activity index and the CRP.
After 3 weeks, they reached remission in the EENG 9 patients and in the
PENG 8 patients (p < 0.01). The Bristol simple activity index improved in
the two groups (EENG; 91.7%, PENG; 86.7% (p = 0.35)), Similarly; VHAI
(EENG; 18.5%, PENG; 30.0%, (p = 0.23)), and CRP (EENG; 58.3%, PENG;
57.1%, (p = 0.49)).
Richard A. Wright et al.
1990 [45] RCCT
11/-
M 7
F 4
ACT
CD
EENG/PNG
6/5
14 US
EENG: Elemental enteral
feeding “Vital”
PNG: Determined peripheral
parenteral nutrition.
CDAI, standard anthropometric
parameters, nitrogen balance
studies and chemical profiles.
CDAI improved significantly in both groups. Plasma transferrin levels and
total lymphocyte count improved in the EENG group (p < 0.05). No
significant differences in weight gain.
Giaffer MH et al.
1990 [46] RCCT
30/38
M 8
F 22
ACT
CD
AG/PG
16/14
28 UK
AG: Amino acid diet
“Vivonex”.
PG: Polymeric diet “Fortison”.
Administration: nasogastric
tube. Water was allowed.
CDAI, total body weight, MAMC,
TSF and biochemical
measurements such as serum
albumin.
12 (75%) AG patients achieved remission at 10 days, compared with 5
(35.8%) in the PG group (p = 0.03). CDAI decreased significantly in the AG
group, not the PG group. The mean weight gain in both groups was similar.
Mean serum albumin increased from 26 g/L to 33 g/L (p < 0.001). Also, there
were significant changes in ESR and AAGP in both groups.
Abad-Lacruz A et al.
1990 [47] RCCT
22/32
M 15
F 14
ACT
IBD
PG/TPNG
16/13
NI ES
PG: Polymeric diet high in
nitrogen “UNIASA” by
nasogastric tube.
TPNG: Specific total parenteral
nutrition by a central vein.
Biochemical measurements (total
serum bilirubin, alkaline
phosphatase, GGT, ALT, and AST)
and VHAI and the Truelove and
Witts index were measured.
PG had a significant increase in serum albumin concentration (32 ± 1 to 38.2
± 1.6 g/L; p < 0.01). There was lower disease activity in both groups (3.31 ±
0.15 to 2.31 ± 0.24, p < 0.05 in GP; and 3.38 ± 0.21 to 2.61 ± 0.27, p < 0.05 in
TPNG). 8 (5 CD and 3 UC) of 13 patients (61.5%) in the TPNG group
developed abnormalities in LFT, while in the PG group only occurred in 1 of
16 patients (6.2%) (p = 0.002).
Greenberg GR et al.
1988 [48] RCCT
51/30
M 25
F 26
ACT
CD
TPNG/ENG/PPNG
17/19/15
21 CA
TPNG: Total parenteral
nutrition, more water, plus
daily one ampoule of vitamins.
ENG: formula diet
“Precision-Isotonic”.
PPNG: Unrestricted diet and a
partial protein/calorie
parenteral nutrition.
CDAI, nutritional assessment and
biochemical measurements
(hematocrit, blood glucose, serum
electrolytes, creatinine,
magnesium and albumin).
The average CDAI decreased (p < 0.01) with no significant differences
between groups. Remission rates to discharge were equivalent among the
three groups: 12 patients in TPNG, 11 patients in ENG and 9 patients in
PPNG and oral diet (X2 1.42 and 1.15; p = n/s). Remission rates of 42% in
TPNG, 55% in EN and 56% in PPNG at 12 months were equivalent and not
influenced by the type of nutritional support initially administered. At 12
months, 18 patients (35%) required surgery, 17 (34%) were medically treated
for relapse, and 16 (31%) had sustained remission.
Harries AD et al.
1983 [49] RCCT
28/37
M 17
F 11
ACT
CD
G1/G2
14/14
120 GB
G1: 2 months ordinary diet
followed by 2 months
supplementation with the
non-elementary low-waste
formula “Guarantee Plus”.
G2: same intervention than G1
with invested order.
Nutritional measurements (height,
weight, MAMC and thickness of
the skin fold), biochemical
measurements (serum prealbumin,
serum, red cell folate, creatinine
height index, platelets, T
lymphocytes, etc.) and urine tests
parameters.
The general effect of EN during the 2 months was to increase serum
albumin, serum protein and prealbumin levels, creatinine height index and
T-lymphocyte count. With EN decreased levels of orosomucoids and serum
alkaline phosphatase and its activity (p < 0.05)
Patients felt better when they received EN, although their monthly
symptom scores showed no significant benefit.
P/d: Period (days); CC: ISO country codes; UNRCT: Uncontrolled and non-randomized clinical trial; NRCCT: Non-randomized controlled clinical trials; RCCT: Randomized controlled
clinical trials; UCT: Uncontrolled clinical trial; IBD: Inflammatory bowel disease; EG/CG: Experimental and Control Group; UC: Ulcerative colitis; EN: Enteral nutrition; CD: Crohn’s
disease; ACT: Active disease; REM: Disease in remission; M: Male; F: Female; CDAI: Crohn’s disease activity index; VHAI: Van Hees activity index; CRP: C-reactive protein; ESR:
erythrocyte sedimentation rate; BMI: Body mass index; HBI: Harvey-Bradshaw Index, SCFA: Short chain fatty acid, SGA: Subjective global assessment; WBC: White blood cells, CT:
computed tomography exam, HB: Hemoglobin; IBDQ: Inflammatory bowel disease questionnaire; IOIBD: International Organization of Inflammatory Bowel Disease rating; NRI:
Nutritional risk index; UNP: Urea Nitrogen appearance rate; RQ: Respiratory quotients; REE: resting energy expenditure; CCK: Cholecystokinin; AAGP: Alpha-1 acid glycoprotein; %IBW:
Percentage of ideal body weight; MAMC: Mid-arm muscle circumference; TSF: Triceps skinfold thickness; HEEH: Home elemental enteral hyperalimentation; GGT: γ-glutamyltransferase;
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LFT: Liver function test; TNF: Tumor necrosis factor; IL: Interleukin; htMAT: hypertrophied messenteric adipose tissue;
PTH: Parathyroid hormone; IBDNF: Inflammatory bowel disease nutrition formula; EPA: eicosapentaenoic acid; CDAS: Crohn’s disease activity score.
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3.2. Meta-Analysis and Meta-Regression
Only 11 clinical trials had common quality and variables needed to be used in the meta-analysis.
These 11 trials worked with a total of 15 groups. The final size of the sample was comprised of
272 individuals, all with CD, to which an EN treatment had been given. The common variables
were the CDAI, the CRP, and the ESR, and the co-variables type of nutrition, age, and duration of
the intervention. Figure 5 shows the effect size of the use of EN. For the three indicators of disease,
the effects were positive when comparing the situation at the start and finish of the treatment with EN
independently, if the situation with fixed effects (less probable) or random effects (more acceptable)
is considered.
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The influence of each study on the results of the meta-analysis are shown on Table 2, considering 
a model of random effects. Figure 6 shows this influence through the Baujat plot. The numbers shown 
in the figure correspond to the articles shown in the table in the ID column. 
Table 2. Influence analysis in meta-analysis using leave-one-out method (random effect). 
    Meta-Analysis for: 
Effect Size (%Heterogeneity) 
ID Omitting KN n CDAI CRP ESR 
1 M.H. Giaffer et al. 1990 Pol 14   13.0 (96.8%) 
2 M.H. Giaffer et al. 1990 Elm 16   13.1 (93.7%) 
3 D. Rigaud et al. 1991 Pol 15   11.2 (97.6%) 
4 D. Rigaud et al. 1991 Elm 15   10.4 (97.6%) 
5 F. Glez.-Huix et al. 1993 Pol 15  20.0 (97.4%) 11.1 (97.6%) 
6 D. Royall et al. 1994 Elm 19  22.2 (95.1%)  
7 D. Royall et al. 1994 Pol 21  22.3 (97.4%)  
8 Teahon K et al. 1995 Elm 19   11.0 (97.6%) 
9 S. Verma et al. 2000 Pol 10 136.9 (94.0%) 17.5 (97.3%) 11.5 (97.6%) 
10 S. Verma et al. 2000 Elm 11 128.0 (97.2%) 21.9 (97.6%) 10.9 (97.6%) 
11 D. M. Wiese et al. 2011 Pol 20 162.3 (97.8%)   
12 Yun Feng et al. 2013 Pol 8 150.3 (97.9%) 19.7 (96.6%)  
13 Zhen Guo et al. 2013 Pol 13 146.7 (97.8%) 19.6 (97.5%) 10.4 (97.6%) 
14 Dong Hu et al. 2014 Elm 59 162.7 (92.6%) 21.5 (97.4%) 9.8 (91.2%) 
15 C. Walton et al. 2016 Elm 17  20.1 (97.6%)  
 Pooled estimate   145.7 (97.4%) 20.5 (97.2%) 11.3 (97.4%) 
KN: Kind of nutrition; Pol: Polymeric nutrition; Elm: Elemental nutrition; CDAI: Crohn’s disease 
activity index; VHAI: Van Hees activity index; CRP: C-reactive protein; ESR: erythrocyte 
sedimentation rate. 
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The influence of each study on the results of the meta-analysis are shown on Table 2,
considering a model of random effects. Figure 6 shows this influence through the Baujat plot.
The numbers shown in the figure correspond to the articles shown in the table in the ID column.
Table 2. Influence analysis in meta-analysis using leave-one-out method (random effect).
Meta-Analysis for:
Effect Size (%Heterogeneity)
ID Omitting KN n CDAI P ESR
1 M.H. Giaffer et al. 1990 Pol 14 13.0 (96.8%)
2 M.H. Giaffer et al. 1990 Elm 16 13.1 (93.7%)
3 D. Rigaud et al. 1991 Pol 15 11.2 (97.6%)
4 D. Rigaud et al. 1991 Elm 15 10.4 (97.6%)
5 F. Glez.-Huix et al. 1993 Pol 15 20.0 (97.4%) 11.1 (97.6%)
6 D. Royall et al. 1994 Elm 19 22.2 (95.1%)
7 D. Royall et al. 1994 Pol 21 22.3 (97.4%)
8 Teahon K et al. 1995 Elm 19 11.0 (97.6%)
9 S. Verma et al. 2000 Pol 10 136.9 (94.0%) 17.5 (97.3%) 11.5 (97.6%)
10 S. Verma et al. 2000 Elm 11 128.0 (97.2%) 21.9 (97.6%) 10.9 (97.6%)
11 D. M. Wiese et al. 2011 Pol 20 162.3 (97.8%)
12 Yun Feng et al. 2013 Pol 8 150.3 (97.9%) 19.7 (96.6%)
13 Zhen Guo et al. 2013 Pol 13 146.7 (97.8%) 19.6 (97.5 ) 10.4 (97.6%)
14 Dong Hu et al. 2014 Elm 59 162.7 (92.6%) 21.5 (97.4 ) 9.8 (91.2%)
15 C. Walton et al. 2016 Elm 17 20.1 (97.6 )
Pooled estimate 145.7 (97.4%) 20.5 (97.2 ) 11.3 (97.4%)
KN: Kind of nutrition; Pol: Polymeric nutrition; Elm: Elemental nutrition; CDAI: Crohn’s disease activity index;
VHAI: Van Hees activity index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.
The results show that the articles did not influence the results in the case of the CDAI and the
ESR, however, study 6 (D. Royall et al. 1994 with Elemental Nutrition) and to a lesser degree, study 12
(Yun Feng et al. 2013 with Polymeric Nutrition) may compromise the results of the meta-analysis for
the CRP. However, the heterogeneity, omitting these works, was 95.1% and 96.6% when compared to
the overall 97.2%, therefore, a great influence of the CRP on the meta-analysis could not be determined.
A funnel plot represents the effects observed in the different studies (x-axis), and the standard error
(y-axis). In the absence of heterogeneity and publication bias, the dots shown in the funnel plot should
jointly adopt the aspect of a funnel, with the wider part corresponding to the smaller and more precise
studies. A lack of symmetry could be due to this publication bias. The funnel plot is shown in Figure 7,
where a lack of symmetry can be observed. Therefore, the non-parametric analysis proposed by Duval
and Tweedie to analyze this asymmetry should show a lack of articles, and therefore a publication bias.
Nutrients 2019, 11, 2657 14 of 21
The results of this non-parametric analysis for the fixed-effects model and the random-effects model
are shown in Table 3. These results show a possible publication bias in the three variables studied, if a
fixed-effects model is assumed; however, the random-effects models did not show this bias.Nutrients 2019, 11, x FOR PEER REVIEW 17 of 24 
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Table 3. Numb r of studies that should be added and the estimated effect size.
Trim-and-Fill Method Copas Method
Fix Model Random Model Random Model
Nº Studies Effect SizeEstimated 95%CI Nº Studies
Effect Size
Estimated 95%CI Nº Studies
Effect Size
Estimated 95%CI
CDAI 2 98.9 [43.9;153.8] 0 No Changes 0 No Changes
CRP 3 15.3 [9.7;20.9] 0 No Changes 4 18.0 [12.1;23.9]
ESR 5 19.3 [11.2;27.4] 0 No Changes 0 No Changes
Crohn’s disease activity index (CDAI); C-reactive protein (CRP); and erythrocyte sedimentation rate (ESR).
With respect to the meta-regression, the results are shown in Table 4. There was a dependence of
the CDAI score with the period, losing efficacy in prolonged interventions (p < 0.05). The CRP showed
better results in the EN when using polymeric formulas that were elemental (p < 0.001).
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Table 4. Meta-regression.
Result Co-Variable Test ofModerators
Intercep KN * QM p-Value
CDAI 167.9 −33.8 0.289 0.591
CRP 13.7 12.6 3.977 <0.001
ESR 12.9 −3.0 0.106 0.745
Intercep Age QM p-Value
CDAI 225.5 −2.38 0.203 0.652
CRP 52.9 −1.0 0.985 0.321
ESR 48.3 −1.1 1.555 0.212
Intercep Period QM p-Value
CDAI 235.5 −1.9 5.662 0.017
CRP 21.4 −0.0 0.006 0.941
ESR 2.5 0.2 1.551 0.213
KN: Kind of nutrition, * Basis elemental enteral nutrition. Crohn’s disease activity index (CDAI), C-reactive protein
(CRP), and erythrocyte sedimentation rate (ESR).
4. Discussion
Our results included 30 studies (1070 participants). All trials included had a broad scope and had
a very varied methodological and clinical heterogeneity. The variables collected were very diverse,
with CDAI, CRP, and ESR being the most common. The sample sizes of the studies included were
generally small (n < 30), thus, a meta-analysis was needed in order to arrive at better conclusions.
A cure for IBD is not known, however, there is evidence of remission and improvement of the
symptoms with EEN, which implies the exclusive consumption of an elemental or polymeric substance
for many weeks [50], as shown by many of our results. Despite the lack of correlation between IBDQ
and the CDAI, correlations were observed between both indexes starting at week 4 of the treatment. A
study that focused on the gall bladder was even found, which showed its improvement after day 36 of
treatment administration; therefore, aside from reducing the activity or inducing the remission of the
disease, this diet could have beneficial effects on organs related with the digestive system [23,25].
The EN formulas tended to contain macronutrients such as amino acids or simple carbohydrates,
along with micronutrients such as vitamins. The proteins, carbohydrates, and fats do not reach the
ilium or the colon as they are absorbed in the duodenum and jejunum. As for the amino acids they
contain, they were named as elemental formulas if they contained free amino acids, semi-elemental if
they contained peptides, and polymeric if they contained whole proteins [51]. Different formulations
exist, but the ones that do seem to have a positive effect on the maintenance and remission of the
disease are elemental and polymeric diets [10,22]. The efficacy of an EN diet does not depend much on
it being elemental or polymeric, as shown by some of our results [42,44], since, a priori, both have
the same potential for inducing a remission [32,39,46]. However, the meta-regression conducted
indicated that a polymeric diet could decrease the CRP better than an elemental one. Additionally, a
distinction could be made between them when looking at the economic burden entailed by the use of
one or the other and the acceptability by the patients, meaning that, in the adherence to the dietary
treatment, the polymeric ones tend to be more accepted by the patients, as they are better tasting [52,53].
The elemental foods are less tolerated with mouth feeding, and generally require a nasogastric tube,
which entails complications and patient discomfort. In contrast, the polymeric EN is more tolerable
through the mouth by patients, making it the first option for the ill [33,54].
As for the formulation of the EN, studies have also been conducted on the benefits or not of an
EN diet rich in fats as opposed to an elemental EN. Just as in other studies, the results of the clinical
trials are controversial. Some studies have demonstrated the beneficial effect of the enteral formula
rich in fats [55], while others did not show any effect [56] or less beneficial effects [29]. Despite what
has been said, some studies have suggested that an EN high in fats could improve gastrointestinal
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motility and improve the ilium after an operation [57], reducing damage to the intestinal mucosa
barrier and the underlying mechanism that could be associated with its antioxidant action after surgical
intervention [58].
EEN, combined with some types of medication such as antibiotics [59], seem to improve the
disease’s symptoms. Just as shown by our results, EN combined with other types of pharmaceuticals
such as prednisone, corticosteroids, and sulfasalazines show a significantly continuous high rate of
remission [41,60]. On the other hand, the combination of EN with steroids does not seem to have
significant differences in the probability of a relapse [40], perhaps because the steroids do not address
the damage produced in the intestinal mucosa, which is the greatest predictor of complications over
time [61,62].
Although the mechanism that nurtures the healing of the mucosa by the EN has not been
completely determined as of yet, it has been shown that a polymeric formula was as effective as the
Infliximab inhibitor of tumor necrosis factor (TNF)-α, and is higher than the hydrocortisone in the
maintenance of the function of the intestinal barrier [63]. This is perhaps the reason why significant
differences were not found in a study conducted by Gasull et al. in 2001 that utilized two polymeric
EN formulas, with the response being similar in both [30]. Additionally, in another study conducted
with two polymeric formulas for five weeks, a significant relationship was not found between the
treatment with different EN and the changes produced at the level of the disease’s activity [37].
As for the use of elemental and semi-elemental EN, the results were very similar. For example,
Mansuf et al. achieved the clinical remission of 16 patients in four weeks with both formulas, and the
reduction of the CRP was significant in both groups [36]. The mechanism of action of the semi-elemental
diet could be multifunctional, just like as the elemental one, decreasing the intestinal permeability
and thus decreasing the loss of fluid. The semi-elemental diet could also reduce the commensal
intestinal bacteria that play a role in intestinal inflammation [64,65]. Thus, the use of these types of
diets is advisable, either with the use of an elemental or semi-elemental formula for the management
of different gastro-intestinal disorders [66].
In 2013, Yun Feng et al. [24] found significant differences between groups subjected to EEN and EN
plus an oral diet, although it is interesting to note how the patients refer to a greater subjective well-being
when they take EN together with the oral diet when compared to those who are not treated with
supplemented EN, despite the biochemical parameters being very similar [21,49]. Some studies suggest
that a partial enteral nutrition supplemented with different diets such as elimination, anti-inflammatory,
auto-immune diets, or diets low in FODMAP (Fermentable Oligo-, Di-, Mono-saccharides and Polyols)
could be beneficial for UC and CD [25,32], although larger controlled assays are needed to back their
use [67]. Even patients who were subjected to EN before their operation experienced benefits, not only
in their nutritional state, but also with a reduction of inflammation in their disease [68], with patients
also experiencing improvements after said intervention [27].
Historically, EN was used and is used as a complementary nutritional treatment for patients
with complicated IBD that leads to worrying malnutrition, thus improving their nutritional state [53].
However, the meta-regression from our study showed an inverse relationship between the period of
treatment with EN and the improvement shown through the CDAI, that foreseeably, the patients who
are subjected to prolonged EN could stop noticing its benefits.
The EN was utilized as an induction therapy for active IBD [53], but it is important to know
which EN formulas can be used to boost their anti-inflammatory effects, as there is evidence that
supplementary EN is not sufficient for inducing remission, so that it would have to be used exclusively
to be able to obtain its anti-inflammatory effect [69,70]. At present, it is well-established that EEN has a
strong anti-inflammatory effect with a reduction in the systemic and mucosa inflammatory parameters
in a few days, however, the EEN as a long-term therapy is still a challenge, given its lack of palatability
and the lack of data to analyze the efficiency of EEN as a maintenance diet [71].
Diverse studies have shown that clinical remission and healing of the mucosa is possible through
different nutritional regimes [72]. As for the debate about which is healthier, EN or PN, our results
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showed that there are studies in which the effectiveness of both seems to be significantly the same for
the improvement of the CDAI [45,48]. Bearing in mind that the dietary antigens could be important
stimulants for the immune system of the mucosa, intestinal rest with total parenteral nutrition (TPN) is
considered as the main option for achieving this rest and for correcting possible nutritional deficits [73];
however when compared to the EN, it does not seem to provide greater benefits. In fact, in one of the
studies included in our review [47], EN was the one that seemed to provide the greatest benefits to the
patients and to reduce the costs, personal as well as economic, of the different dietary treatments [74].
According to European guidelines, the acceptability and the obligatory compliance of the EN are
the greatest obstacles found by different researchers when dealing with EN studies. There are clear
differences between the studies shown in terms of healing of the mucosa, and therefore the remission
of the activity of the disease, which makes them difficult to compare. What is known, however, is that
the EEN is a real alternative to immunosuppressive therapy, which exerts its main therapeutic effect
on the microbiota, thus reducing intestinal permeability, enhancing barrier defense, and promoting a
reduction of pro-inflammatory cytokines [75,76].
This study is not exempt of limitations. With respect to the systematic review, seven articles were
not recovered, so our results could be altered. However, the small variability observed through the
meta-analysis implies that these articles could substantially vary the results obtained, and in fact,
the sensitivity study that analyzed the publication bias showed little alterations on the effect size
as well as its confidence interval. Although the quality of these studies has not been introduced in
the meta-regression, all the articles that were utilized with this technique were considered to have
sufficient quality, so we do not believe that the quality could introduce bias in the findings.
5. Conclusions
EN has been shown to have efficacy for the treatment of CD and is compatible with other
medicines. As for the CDAI or the rates of remission, there were no differences between EN and PN.
Polymeric formulas, when compared to elemental ones, have shown better results with respect to
the CRP. The long-term treatment could dilute the good CDAI results that are obtained at the start of
EN treatment.
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